Corvus Pharmaceuticals GAAP EPS of -$0.15 misses by $0.02
Source: SeekingAlpha
2026-03-12 16:02:26 ET
- Corvus Pharmaceuticals press release ( CRVS ): Q4 GAAP EPS of -$0.15 misses by $0.02 .
- As of December 31, 2025, Corvus had cash, cash equivalents and marketable securities of $56.8 million as compared to $52.0 million as of December 31, 2024. Cash, cash equivalents and marketable securities as of December 31, 2025 does not include approximately $189.4 million in net proceeds received in a financing completed on January 23, 2026. Based on its current plans, Corvus expects its cash to fund operations into the second quarter of 2028.
Read the full article on Seeking Alpha
For further details see:
Corvus Pharmaceuticals GAAP EPS of -$0.15 misses by $0.02
Corvus Pharmaceuticals Inc.
NASDAQ: CRVS
CRVS Trading
0.28% G/L:
$14.24 Last:
507,763 Volume:
$14.10 Open:
CRVS Latest News
CRVS Stock Data
$1,643,805,638
59,046,523
N/A
41
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
